NMOSD Attack and Disability Risk Calculator

Neuromyelitis optica spectrum disorder (NMOSD) attacks are considered unpredictable and often result in cumulative and permanent neurological damage.1 The NMOSD Attack and Disability Risk Calculator is a new prognostic tool that aids in predicting the likelihood of attacks in individuals with aquaporin-4 antibody positive (AQP4+) NMOSD using published data from Palace J, et al. Brain. 2019;142(5):1310-1323.2

Background

  • Risk estimates were calculated using a large multicentre dataset of 441 patients from the United Kingdom, United States of America, Japan, and Martinique who collectively experienced 1,976 attacks.2
  • Patients were treated with chronic prednisolone/prednisone, azathioprine, mycophenolate, rituximab, methotrexate, or combination of these options from onset.* The efficacy of each IST was not individually assessed.2
    • Of these patients, 20 were given rituximab as a first-line treatment.2
    • Agents like eculizumab, inebilizumab, or satralizumab were not included due to their unavailability at the time of analysis.
  • Disability endpoints were evaluated as a composite of one- and two-eye blindness and a composite of EDSS 8.0 and death.2

* These therapies are not indicated for the treatment of NMOSD in Canada.

 
For more information, review the publication here.
Alexion Privacy Notice

Access and use of this Site is intended exclusively for the territory of Canada and is subject to all applicable laws and regulations therein. By accessing and browsing this Site from a different location, you accept, without limitation or qualification, that the information contained in this Site might not be in accordance with the laws and regulations of your Country.

This tool was developed in partnership with Alexion Pharmaceuticals Canada, Inc.
ALEXION® and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc.
Copyright ©2021, Alexion Pharmaceuticals, Inc. All rights reserved.

 
back arrow
 
EN | FR

Choose the relevant characteristics to display the likelihood (%) of experiencing attacks and disability over time

Patient Characteristics

Sex
Male
Female
 
Ethnicity
African
Caucasian
Japanese
 
Age (in years)
≤ 35
36-48
> 48
 
Onset Attack Type
Optic
Neuritis
Transverse
Myelitis
Brain
Stem
 
Second Attack Type Experienced Within First 2 Years Since Disease Onset
Not
applicable
Optic
Neuritis
Transverse
Myelitis
Brain
Stem
 
Submit
Reference:
1. Kimbrough DJ, et al. Multiple Sclerosis and Related Disorders.
2012;1(4):180-187.
2. Palace J, et al. Brain. 2019;142(5):1310-1323.
CA/SOL-N/0118E

Alexion Privacy Notice

Access and use of this Site is intended exclusively for the territory of Canada and is subject to all applicable laws and regulations therein. By accessing and browsing this Site from a different location, you accept, without limitation or qualification, that the information contained in this Site might not be in accordance with the laws and regulations of your Country.

This tool was developed in partnership with Alexion Pharmaceuticals Canada, Inc.
ALEXION® and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc.
Copyright ©2021, Alexion Pharmaceuticals, Inc. All rights reserved.

 
 

Likelihood (%) of developing attacks and disability

Patients who have not reached the disability endpoint but experienced one attack within two years since disease onset

Patients who have not reached the disability endpoint or experienced any attack two years after disease onset

All
Attacks		 Optic
Neuritis		 Transverse
Myelitis		 Brainstem EDSS Score Blindness
6 ≥ 8
Risk over next
2 years
Risk over next
3 years
Risk over next
5 years
Risk over next
10 years
Reset
 
The confidence of the risk estimation is dependent on both the size of the dataset and the diversity of the population (e.g., age, sex, ethnicity). The data used to generate these estimates may not be completely representative of the disease course and disability in the community. Biases may exist due to patients lost to follow-up. This may lead to loss of some patients with milder disease and could explain the variability in mortality rates depending on the completeness of data obtained.2

EDSS, Expanded Disability Status Scale; IST, immunosuppressive treatment.
References:

  1.   Kimbrough DJ, et al. Multiple Sclerosis and Related Disorders. 2012;1(4):180-187.
  2.   Palace J, et al. Brain. 2019;142(5):1310-1323.
CA/SOL-N/0118E